CNR1 and obesity due to melanocortin 4 receptor deficiency: Inverse agonists (antagonism) of CB1R were developed 20 years ago as treatments for obesity: however, rimonabant that did come into use for that purpose was quickly withdrawn because of severe adverse psychiatric effects (Sam et al., 2011).